Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

UFS Chemistry wins dti award
2010-11-02

At the awards ceremony are, from the left: Director-General of Trade and Industry Mr Tshediso Matona, Prof. Andreas Roodt and the Deputy-Minister of Trade and Industry, Ms Bongi Maria Ntuli.
Photo: S Osman

The research group of Prof. Andreas Roodt, Head of the Department of Chemistry at the University of the Free State (UFS) in Bloemfontein, won the first prize in the category Development of Small Medium and Micro-Enterprises (SMME) at the annual Department of Trade and Industry’s (dti) award ceremony.

Prof. Roodt received the prize for the high-technology project Development of novel nuclear pharmaceuticals in the Technology and Human Resources for Industry Programme (THRIP).

The Deputy-Minister of Trade and Industry Bongi Maria Ntuli, and Director-General Tshediso Matona presented the prize at the gala dinner held at Gallagher Estate, Gauteng in October 2010.

The dti’s Annual Technology Awards recognise excellence in research and aim to raise awareness on the benefits of using technology to improve the competitiveness of enterprises, within the local and global arena. Individuals and organisations are recognised for their efforts in advancing and promoting technology interests and emerging enterprises.

The technology awards cover the achievements of three of the dti technology programmes collectively, namely THRIP, managed by the National Research Foundation (NRF); the Support Programme for Industrial Innovation (SPII) managed by the Industrial Development Corporation (IDC); and the Small Enterprise Development Agency (seda) Technology Programme (stp).

Prof. Roodt, also vice-president of the European Crystallographic Association, who has just returned from a series of lectures abroad after being elected Fellow of the Royal Society of Chemistry in the UK, has received funding in excess of R3 million over the past two years to set up a specialised laboratory for synthesising active compounds. Key partners in this project are Dr Gerdus Kemp from PETLabs Pharmaceuticals in Pretoria; Prof. Connie Medlen (pharmacologist), recently appointed affiliate professor at UFS Chemistry; as well as Prof. Deon Visser from the Inorganic Chemistry research group at the UFS.

The research aims to produce new nuclear medicinal agents for the early diagnosis of cancer, heart and brain defects, and even HIV/ Aids.

Two doctoral students, Alice Brink and Marietjie Schutte, are currently actively involved in this project. They are the recipients of prestige scholarships introduced by the UFS Rector and Vice-Chancellor, Prof. Jonathan Jansen, under the UFS Research Initiative (the Advanced Biomolecular Systems Cluster) to complete their Ph.D. studies.

Media Release
Issued by: Lacea Loader
Director: Strategic Communication (actg)
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl@ufs.ac.za  
2 November 2010

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept